OLPs did not affect migraine frequency but did subjectively improve QoL, with authors noting they may have a role as a supportive treatment option for select patients.
The investigational ShiraTronics Migraine Therapy System delivered an average of 9.6 migraine-free days per month, reduced rescue medication use, and improved QOL.
Fremanezumab is now the only CGRP antagonist indicated for prevention of migraine in adults and preventive treatment of episodic migraine in pediatric patients.
The superior tolerability and efficacy of the CGRP-targeting atogepant supports recent calls from the AHS to consider the class as first-line preventive therapy for migraine.